Pathway to affordable, quality-assured sources of pegylated interferon alpha for treating hepatitis C
Journal Title: Generics and Biosimilars Initiative Journal - Year 2013, Vol 2, Issue 4
Abstract
Introduction: The current pipeline of promising oral hepatitis C drugs could lead to a revolution in treatment for this disease in both developed and developing countries. At present, the recommended treatment is pegylated interferon alpha (in combination with ribavirin). However, the limited availability and high cost of this medicine is a major barrier to expanding access to treatment in developing countries. Methods: We compiled information on marketed biosimilars and alternative pegylated interferon alpha products and price information on the innovator products in several developing countries. In parallel, we conducted a review of the biosimilars guidance by World Health Organization (WHO) and by selected national drug regulatory agencies. Results: The price of the innovator products ranges from US$200 to US$375 per vial, meaning that a full (48 weeks) treatment course costs US$10,000–US$20,000 per patient in the surveyed countries. So far, only a few countries have carved out exceptions to this high price. By allowing generics competition Egypt lowered the price of the innovator products to around US$40 per week, while Iran used technology transfer to establish local production and ensure availability within its health system. We have indentified six pegylated interferon alphas, which could be evaluated to expand the pool of quality assured products. Conclusion: WHO added pegylated interferon alpha to its Essential Medicines List released in July 2013, but other steps – and more progressive WHO guidance – are needed to ensure more immediate treatment options for patients in developing countries. In particular, WHO should re-examine its 2009 ‘Guidelines on Evaluation of Similar Biotherapeutic Products’ in light of recent international debates about clinical comparative exercises and of accumulated regulatory experience on biosimilars. In parallel, WHO should establish an evaluation scheme of biological drugs to promote product availability and affordability. These considerations also bear on access problems for other essential and lifesaving biological drugs.
Authors and Affiliations
Barbara Milani, Sara Gaspani
Keywords
Related Articles
- EP ID EP354754
- DOI 10.5639/gabij.2013.0204.053
- Views 102
- Downloads 0
Generic and therapeutic orphans
This commentary discusses the need to develop methods to ensure the availability of non-profitable, off-patent medicines to children and other populations. The history and some of the shortcomings of legislative attempts...
PMDA update: the current situation and future directions
The Pharmaceuticals and Medical Devices Agency (PMDA) is a Japanese drug regulatory agency, sharing responsibilities with the Ministry of Health, Labour and Welfare. Its mission is to protect the public health by assurin...
What to look forward to in GaBI Journal, 2014, Issue 2
As mentioned previously, non-biological complex drugs (NBCDs) continue to raise important regulatory and practice issues. This issue of the GaBI Journal contains a number of manuscripts dealing with these products and be...
Promoting access to biosimilars: a public−private partnership model for biosimilar development in underserved populations
Biologicals represent the future of pharmaceutical treatments and innovation. Yet, emerging and developing markets lack access to these often essential medicines. Biosimilar development represents a potential solution to...
Maximizing quality in the manufacture of biologicals
Biological product quality is susceptible to unexpected manufacturing issues, and the resulting variation may impact the safety or efficacy of these medicines and increase risks to patients. These risks can be managed mo...